Feature | September 10, 2012

Baylor Researchers Begin Study of Link Between A-Fib and Cardiac Surgery

September 10, 2012 — Atrial fibrillation (AF) is a common complication of cardiac surgery, occurring in 10 to 40 percent of patients. Recent studies show it to be associated with poorer health following surgery and poorer long-term survival. Furthermore, development of AF after cardiac surgery leads to average additional healthcare costs of $15,000 to $20,000.

As part of an ongoing NIH National Heart Lung and Blood Institute study, Giovanni Filardo, Ph.D., MPH, and his team are executing a large national multicenter study assessing the effectiveness of optimal preventive and management strategies (based on American Heart Association/American College of Cardiology/European Society of Cardiology [AHA/ACC/ESC] and AACP guidelines) and their impact on the incidence of post-CABG (coronary artery bypass graft surgery) AF and long-term survival. Filardo is director of epidemiology at Baylor Health Care System’s Institute for Health Care Research and Improvement, and The Bradley Family Endowed Chair in cardiovascular epidemiology at Baylor University Medical Center.

"Currently we do not know what causes post-operative AF, nor how to identify patients at high risk and effectively prevent or mitigate this complication," said Filardo. "These are the questions that the study seeks to answer."

The retrospective study will look at patients who underwent isolated CABG surgery at Baylor University Medical Center (Dallas), Baylor Heart Hospital (Plano, Texas), Emory University (Atlanta), University of Virginia (Charlottesville, Va.) or Washington University (St. Louis). The study will provide insights into the prevention and management of post-operative AF, allowing healthcare providers to improve survival and decrease costs of care associated with CABG surgery.

More than 100,000 people in the United States and 1.5 million people worldwide undergo isolated CABG surgery each year. "Even taking the conservative estimate of 20 percent of those patients developing AF, the results of this study stand to improve survival for 300,000 people and save as much as $6 billion ($20,000 per person cost attributable to post-operative AF) in healthcare costs each year," said Filardo.

The purpose of the study is to identify the causes of new-onset AF in patients undergoing cardiac surgery, and whether current guidelines for high-risk patients are effective in preventing new-onset AF or if treatment protocols for those patients who do experience the condition are effective in improving survival. The study will be completed in April 2014.

For more information: www.baylorhealth.edu/research

Related Content

common adult CT examinations, computed tomography, diagnostic reference levels, DRLs, radiation dose, achievable dose, AD
News | Radiation Dose Management| February 23, 2017
Using data from the world’s largest computed tomography (CT) dose index registry, researchers have established national...
News | Cardiac Diagnostics| February 17, 2017
Levels of a protein in the blood associated with heart disease are also linked to early-stage brain damage, according...
Edwards Intuity Elite sutureless aortic valve, first implants in Connecticut, WCHN, Western Connecticut Health Network
News | Cardiovascular Surgery| February 16, 2017
Western Connecticut Health Network (WCHN) cardiothoracic surgeons Cary Passik, M.D., and Robert Gallagher, M.D., were...
Medtronic, expanded indication, Freezor Xtra Cryoablation Catheter, AVNRT, atrioventricular nodal re-entrant tachycardia
Technology | Ablation Systems| February 16, 2017
Medtronic plc announced the U.S. Food and Drug Administration (FDA) has approved its Freezor Xtra Cryoablation Catheter...
Mercator MedSystems, DANCE trial data, ISET, LINC, Bullfrog Micro-Infusion Device
News | Peripheral Arterial Disease (PAD)| February 15, 2017
Mercator MedSystems announced that the national co-principal investigators of the company’s DANCE trial each presented...
heart team, hybird OR, structural heart team

The heart team approach was first used on a large scale in the CoreValve and Sapien TAVR trials and helped lead to excellent outcomes in high-risk patients.

Feature | Hybrid OR| February 15, 2017 | Dave Fornell
In the current era of healthcare reform and the push toward evidence-based medicine to both lower costs and improve p
Biotronik, ProMRI Configurator tool, MR-conditional cardiac devices, ProMRI SystemCheck
Technology | Implantable Cardiac Monitor (ICM)| February 14, 2017
Biotronik has developed an online tool that streamlines the workflow for physicians selecting the right magnetic...
News | Hypertension| February 13, 2017
Vascular Dynamics Inc. (VDI) announced that the U.S. Food and Drug Administration (FDA) has approved the company’s...
Xarelto, rivaroxaban, COMPASS study, ends early,
News | Antiplatelet and Anticoagulation Therapies| February 09, 2017
February 9, 2017 — Janssen Research & Development LLC (Janssen) announced that the Phase 3 COMPASS trial is stopp
Medtronic, IDE approval, IN.PACT Admiral drug-coated balloon, DCB, end-stage renal disease
News | Drug-Eluting Balloons| February 08, 2017
Medtronic plc announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug Administration...
Overlay Init